Eudragit-Based Nanoparticles for Oral Drug Delivery.

Filipa Bettencourt, Patrícia C Pires, Francisco Veiga, Ana Cláudia Paiva-Santos, Amélia C F Vieira

Abstract readReview

In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Filipa BettencourtDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.

Patrícia C PiresLAQV/REQUIMTE, Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.ORCID 0000-0003-0036-4894

Francisco VeigaDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.

Ana Cláudia Paiva-SantosDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.ORCID 0000-0003-2710-6000

Amélia C F VieiraDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.ORCID 0000-0003-3747-9708

Funding

This work was financed by National Funds through FCT/MCTES-Portuguese Foundation for Science and Technology within the scope of the project UIDB/50006/2025-https://doi.org/10.5 4499/UID/50006/2025. This work was financed by National Funds through FCT/MCTES-Portuguese Foundation for Science and Technology within the scope of the project UIDB/50006/2025-https://doi.org/10.5 4499/UID/50006/2025.

6 · The paper itself

Abstract

The development of oral drug delivery systems has become a major priority for pharmaceutical technology, driven by the growing demand for medicinal products that improve compliance, enhance therapeutic efficacy, and minimise drug-related adverse effects. Therefore, the ability to modulate drug release kinetics through systems capable of controlled and targeted delivery is crucial. In this context, Eudragit-based nanoparticles have demonstrated great potential in enhancing drug stability, controlling release profiles, and improving site-specific targeting in the gastrointestinal tract. Polymethacrylate copolymers (Eudragit

Indexed as

controlled drug releaseEudragitnanoparticlesoral drug deliverypolymethacrylate

Identifiers

PMID42514891

DOI10.3390/pharmaceutics18070813

PMCPMC13415009

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.